

REVIEW

Open Access



Immune modulation of some autoimmune diseases: the critical role of macrophages and neutrophils in the innate and adaptive immunity

Kely Campos Navegantes¹, Rafaelli de Souza Gomes¹, Priscilla Aparecida Tártari Pereira², Paula Giselle Czaikoski³, Carolina Heitmann Mares Azevedo¹ and Marta Chagas Monteiro^{1*}

Abstract

Macrophages and neutrophils are key components involved in the regulation of numerous chronic inflammatory diseases, infectious disorders, and especially certain autoimmune disease. However, little is known regarding the contribution of these cells to the pathogenesis of autoimmune disorders. Recent studies have aimed to clarify certain important factors affecting the immunogenicity of these cells, including the type and dose of antigen, the microenvironment of the cell-antigen encounter, and the number, subset, and phenotype of these cells, which can prevent or induce autoimmune responses. This review highlights the role of macrophage subsets and neutrophils in injured tissues, supporting their cooperation during the pathogenesis of certain autoimmune diseases.

Keywords: Macrophages, Neutrophils, Autoimmunity, Autoimmune disease, Inflammation

Background

Epithelial and mucosal barriers, natural antimicrobial products, immune cells, pattern-recognition receptors, and soluble products, cytokine and opsonins (e.g., complement) are critical innate components. In this context, neutrophils and macrophages play an important role in induction either pro-inflammatory or anti-inflammatory responses into the inflammatory site [1, 2]. Thus, these cells are key components involved in the development of inflammatory responses of diverse pathological conditions, such as chronic inflammatory diseases, infectious disorders, autoimmunity and others diseases [3–5]. Autoimmunity reflects an imbalance between effectors and regulatory mechanisms, including the defective elimination and/or control of innate and adaptive responses and the activation of cells with of varying subsets and phenotypes, such as macrophages and neutrophils, which

release several products into tissue. Thus, this review highlights the role of macrophages subsets and neutrophils in the peripheral tissues, and also further supporting their cooperation during the development of the pathogenesis of T cell-mediated autoimmune disease, as type 1 diabetes mellitus and rheumatoid arthritis.

Macrophages and neutrophils: development and inflammation

Origin and development of neutrophils and macrophages

The first lines of defence against pathogens are the phagocytes cells, in which macrophages and neutrophils are included [6]. Neutrophils, the very short-lived human white blood cells (8–12 h in the circulation and 1–2 days in tissues), are the most abundant leukocytes in blood playing a primary role in the innate immunity [7]. These cells are produced in the bone marrow from multipotential progenitor cells, under the action of numerous mediators in particular growth factors called granulocyte colony-stimulating factor (G-CSF), which are the main regulator of the granulocytogenesis as shown in Fig. 1 [8–10]. The most immature cell of the granulocytic lineage is

*Correspondence: martachagas2@yahoo.com.br

¹ Pharmaceutical Science Post-Graduation Program, Health Science Institute, Federal University of Pará/UFPA, Belém, PA 66075900, Brazil
Full list of author information is available at the end of the article

known as myeloblast. The proliferation and differentiation of these progenitors and these cells depend on hematopoietic cytokines such as G-CSF, gene expression (responsible

for the formation of granular proteins involved in cell function), myeloid transcription factors, forming the myeloid phagocyte system (MYPS) [8, 11, 12].




Fig. 1 Origin and development of macrophages and neutrophils. **a** The generation of macrophages is dependent on hematopoietic growth factor receptor Csf1r (c-fms, M-CSFR, CD115). The known ligands of Csf1r, Csf1/M-CSF and interleukin (IL)-34 are likely both important for the development of the mononuclear phagocyte lineage. On the other hand, hematopoietic cytokines as granulocyte–macrophage colony-stimulating factor (GM-CSF) and granulocyte colony stimulating factor (G-CSF) that promote neutrophil progenitor proliferation and differentiation. **b** Bone marrow neutrophil lineage cells can be divided into three compartments: the stem cell pool (stem cells and pluripotent progenitors), the mitotic pool and the post-mitotic pool. **c** The regulation of Neutrophil egress from de bone marrow by CXCR4 and CXCR2 chemokine ligands, where stromal cells produce C-X-C-motif chemokine ligand (CXCL) 12 that binds to C-X-C-motif chemokine receptor (CXCR) 4, leading to neutrophil retention, while release is mainly mediated by CXCR2. Hematopoietic stem cell (HSC), common myeloid progenitor (CMP), granulocyte–macrophage progenitor (GMP), myeloid progenitor (MP)

Thus, the G-CSF acts by binding G-CSF receptor, a family member of the class I cytokine receptor, promoting the neutrophil's population life cycle that includes its proliferation, differentiation, releasing of mature cells from the bone marrow and survival [9, 10, 13, 14]. In this context, the bone marrow neutrophil's population can be distributed in the stem cell pool, the mitotic pool and the post-mitotic pool [10, 14]. The first to mature are the hematopoietic stem cells and pluripotent progenitors; the next population, the mitotic pool, is composed of granulocytic progenitor cells such as myeloblasts, promyelocytes, and myelocytes. Lastly, mature neutrophils (metamyelocytes) are part of the post-mitotic pool, which constitutes the major source of neutrophils that can be easily mobilized and rapidly recruited to sites of infection [10, 14, 15].

All these populations are in homeostasis that includes a well-preserved equilibrium among granulopoiesis, bone marrow storage and release, intravascular transit, and destruction [14]. Therefore, after the neutrophil production, development and storage in the bone marrow, its releasing includes a transcellular migration from the sinusoidal endothelium to the circulation [14, 16]. Then, among existing mechanisms, the chemokines and their receptors play a key role about the balance between neutrophil release and retention. The major role is played by the stromal derived factor-1 (SDF-1) produced in the bone marrow and its ligation with the C-X-C motif chemokine receptor (CXCR) types 2 and 4. While the interaction of SDF-1 with the CXCR2 leads to the release of neutrophils, the interaction with the CXCR4 produces the opposite effect, leading to the retention of the neutrophils in the post-mitotic pool (Fig. 1b) [10, 17, 18].

After the bloodstream, the neutrophil migrate into the tissues to perform its function. However, near the inflammatory lesions neutrophils adhere to the endothelial wall, leave the blood vessels and actively migrate into the inflammatory focus [10]. This type of cells without external stimuli dies by apoptosis [12]. The process of cells death is a natural endpoint that occurs when the plasma membrane lose its integrity, or in the presence of cell fragments into discrete bodies and in the engulfment of the cell by another [19, 20]. Thus, to maintain the immune homeostasis is necessary the clearance of the apoptotic neutrophils by macrophages [14, 15]. This process is called "efferocytosis" and involves the liver X receptor (LXR), the decreasing in the production of interleukin (IL)-23, IL-17 and G-CSF, whereas its weakened clearance has been associated with autoimmune diseases [10, 21, 22].

The other major defence against pathogens, inflammatory diseases and autoimmune diseases are the macrophages [23]. This type of leukocyte has its origin in


hematopoietic stem cell with a myeloid progenitor forming the mononuclear phagocyte system (MPS) as shown in Fig. 1 [24]. Cytokines, as the macrophage-colony stimulating factor (M-CSF) and hematopoietic growth factor receptor (Csf1) expressed in monocytes, macrophages, mononuclear phagocyte precursors, are the main regulators of the MPS and both important for the development of phagocytic lineage [24, 25]. Therefore, MPS is constituted by monocytes, macrophages and dendritic cells (DC) [24]. Monocytes, precursor of tissue macrophages, are present in the bone marrow, circulation, and spleen, while the macrophages resides in lymphoid and non-lymphoid tissues [24]. However, recent studies suggest that many adult tissue macrophages have their origins during the embryogenic development, not only during the adult phase [26–28].

Thus, the embryonically derived macrophages are firstly detected and developed in the yolk sac being the only leukocyte produced independently of monocytes [29]. Afterward, all immune lineages forming the definitive hematopoietic stem cells (HSCs) that migrate to the foetal liver [27]. The principal site of haematopoiesis just became the bone marrow in the perinatal period [30]. These embryonic—resident tissue macrophages along the adulthood loss the capacity to identify macrophage populations [27]. Then, even with an origin dependent or not of monocytes, macrophages contribute to the homeostasis of the immune system.

Activation of macrophages and neutrophils

In general, monocytes/macrophages contribute to the modulation of the immune response can lead to autoimmunity. These cells are dynamic as to polarize phenotypes of pro-inflammatory and anti-inflammatory cytokines depending on the microenvironment, acting with different physiological functions [31]. Recently, macrophages are subdivided in two main phenotypes: the classically activated macrophages (M1 macrophages) promote tissue inflammation and activated macrophages (M2 macrophages), these last is classified into three subtypes according to their functions: host defence, tissue repair and immunoregulation [32] (Fig. 2).

Classically activated macrophages (M1 macrophages) intermediate host defence against a variety of bacteria, protozoa and viruses and participate in anti-tumour immunity, autoimmune diseases [33, 34]. Lipopolysaccharides (LPS) as certain bacterial products and cytokines such as interferon (IFN)- γ stimulate macrophages to M1 subset. As a result, M1 macrophages induce a strong pro-inflammatory phenotype with the production of cytokines (TNF- α , IL-6, IL-12 and IL-23) and chemokines (CCL-5, CXCL9, CXCL10 and CXCL5), promoting the recruitment of Th1 and Natural



killer (NK) cells. In addition, it has been shown that M1 macrophages up-regulate the intracellular expression of a protein called suppressor of cytokine signalling 3 (SOCS3), which increases the production of reactive oxygen intermediates and nitrogen, the expression of MHC class II molecules and costimulatory molecules [35, 36]. In this perspective, M1 macrophages promote Th1 immune responses, but also contribute to the tissue destruction and tumoricidal activity [37]. Therefore, an over-activation can lead to tissue damage such as occurs in various inflammatory, autoimmune and chronic diseases, including Crohn’s disease, rheumatoid arthritis,

diabetes, multiple sclerosis and autoimmune hepatitis [38–43].

Otherwise, alternatively activated macrophages (M2 macrophages) are involved with immune regulation, tissue remodelling, and elimination of parasites, tumour promotion and autoimmune diseases. The M2 macrophages can be divided into three differing subpopulations: M2a, M2b, and M2c macrophages [44–47]. They are clearly distinct, both functionally and biochemically [47]. In the context, macrophages contribute to the reparative extracellular matrix production, while regulators macrophages express high levels of costimulatory

molecules (CD80 and CD86) and can present antigen to T-cells, although, there are differences among the subtypes M2 macrophages, usually macrophages repairers and regulators exhibit immunosuppressive activity [48].

The M2a macrophage is stimulated by IL-4/IL-13 through the binding of these cytokines to their receptors, which then activates STAT-6 signalling pathway. It also up regulates the histone demethylase JMJD3, by altering of chromatin modifications that induces expression of M2 gene and inhibits M1 gene during tissue repair and anti-inflammatory response [49, 50]. In addition, M2a macrophages up-regulated the Mrc1, resistin-like a (Retnla, Fizz1) and chitinase 3-like 3 (Chi3l3, Ym1) expression, suggesting that these expressions are selective markers of M2a macrophages [51].

M2b macrophages are polarized by combined immune complexes that contain toll-like receptor (TLR) and/or IL-1 receptor agonists [35, 52] and produce high levels of pro-inflammatory cytokines, including IL-1, IL-6 and TNF [53]. M2a macrophages also induce the influx of eosinophils, basophils, Th2 cells and regulatory T-cells by secreting CCL24, CCL17, CCL1 and CCR1 at the site of inflammation [54].

The M2c macrophages are induced by transforming growth factor (TGF)- β , glucocorticoids [37] or IL-10. In this context, IL-10 is secreted by dendritic cells, B cells, cytotoxic T-cells, T-cells, NK cells, mast cells, neutrophils, eosinophils, as well as monocytes/macrophages [55]. The activation mediated by IL-10 acts through a transmembrane receptor complex composed of IL-10R1 and IL-10R2. Thus, the IL-10/IL-10R1 interaction changes the cytokine conformation leading to its dimerization with IL-10R2, which activate Jak1/STAT3 signalling pathways [55].

These macrophages are engaged in a complex bidirectional interaction with neutrophils. They also can drive the development of the innate and acquired immune responses by complicated cross-talk with other cells, including natural killer and DC [56]. Various mechanisms underlying the neutrophils' antimicrobial activity, such as phagocytosis, generation of reactive oxygen species (ROS), cytokines, chemokines, lipid mediators, degranulation of antimicrobials and enzymes [57]. In 2004, Brinkman et al. [17] demonstrated that neutrophils generate an extracellular chromatin fibre, called neutrophil extracellular traps (NETs), which disarm and kill extracellular bacteria [58]. The NETs are composed of DNA, histones, amphoterin HMGB1 (high-mobility group box 1), and globular structures that consist in components granules of neutrophils, such as neutrophil elastase (NE), myeloperoxidase (MPO), cathepsin G, proteinase 3, cationic bactericidal permeability increasing protein (BPI), calgranulin, α -defensins, lactoferrin, the


peptide LL-37, pentraxin PTX3, matrix metalloproteinase-9 (MMP-9) and peptidoglycan recognition protein-S (PGRP-S) [59–61].

The mechanisms involved in the NETs formation are not fully elucidated. It was demonstrated that upon activation (by lipopolysaccharide, bacteria, fungi), neutrophils start a programme that leads to their death by a mechanism distinct of apoptosis and necrosis, called NETosis [62]. For this, NE translocates to the nucleus, where it breaks, partially, specific histones, promoting chromatin decondensation [63], and the nuclei of neutrophils lose their shape, and heterochromatin homogenize [15]. The chromatin decondensation is made by the MPO enzyme, probably, due to the synthesis of hypochlorous acid [63]. Moreover, NETs formation depends on the ROS production by NADPH oxidase [22]. This ROS may alter several macromolecules, including DNA, proteins and lipids, making them more susceptible to attack by neutrophil enzymes [64]. In addition, the peptidyl arginine deiminase 4 (PAD4) induced catalyzes deamination of arginine residues in the histones intensifying chromatin decondensation [65, 66]. Finally, the nuclear envelope and the granule membranes disintegrate, allowing the mixing of NET components, then NETs are released as the cell membrane breaks [67].

Initially, the formation of NETs was considered an innate immune response in response to infections. However, recent evidence suggests that these structures are involved in the pathogenesis of various diseases, including autoimmune disorders [62–65]. Regarding to autoimmunity, the molecules present in the NETs or the degradation products of NETs by DNase I can act as auto-antigen [63, 64]. Several groups have proposed that the excessive formation or degradation failure of NETs that lead to the expression of a set of auto-antigens and danger-associated molecular patterns, are important factors in the development of autoimmune responses in predisposed individuals, as shown in Fig. 3 [62–66].

The role of macrophages and neutrophils in the innate and adaptive immunity

Macrophages and neutrophils are qualified phagocytes that correspond to the first lines of defence against pathogens [68]. In general, the neutrophils were associated with acute inflammation, while monocyte/macrophages appear to be associated the chronic inflammation [69]. However, several studies have challenged these dogmas, showing that neutrophil is a key effector cell in the orchestration of the adaptive immunity in the resolution of chronic inflammatory response [70–72], while monocytes/macrophages are important in acute inflammation [73]. In this regards, neutrophils are the first leukocytes that are recruited rapidly into acute infection site, which after their activation,



they kill or phagocytosis foreign bodies and release soluble mediators, as cytokines that induce the recruitment of monocytes to the inflammation site [69, 74, 75]. On this occasion, monocytes would then be recruited following neutrophils to the site of injury and differentiate into macrophages [1]. Certain studies suggested a predominance of monocytes/macrophages that substitutes the neutrophils. This propose a bimodal recruitment pattern that interchange neutrophils to monocytes [76]. However, currently there is evidence that chemoattractant, as MCP-1, produced in situ by tissue monocytes/macrophages rapidly and directly induces the monocytes influx regardless of the presence of infiltrating neutrophils at inflammation site [1]. Thus, neutrophils and monocytes found into the inflammatory site can participate in both the innate and adaptive immune response, displaying several functions described in Table 1.

In this context, monocytes / macrophages play a central role in both adaptive and innate immunity, due these cells play dual role in tissue injury, either injury-inducing or repair-promoting [73]. Thus, macrophages constitute an important class of antigen-presenting cells (APC) that activate adaptive immunity, as well act in phagocytosis, antigen processing and presentation, leading to the activation of T and B cells. These cells also secrete pro-inflammatory, anti-inflammatory, angiogenic, fibrogenic or mitogenic cytokines. These processes cooperate with others immune and progenitor cells to control the initiation, resolution, and repair tissue damage during chronic inflammation [73, 77]. In summary, this cell has a large repertoire of well-characterized abilities and functions both in innate and adaptive immunity, including regulation of inflammatory responses, stimulation of T and B cells, may promote Th1 cells differentiation,

Table 1 General functions of macrophages and neutrophils in innate and adaptive immunity

	Monocyte/macrophage	Neutrophil
Innate immunity	Opsonic recognition [229] Production of pro-inflammatory and anti-inflammatory cytokines [230] Release G-CSF and GM-CSF [231] Excessive release of toxic species (NO, superoxide and MMP) [232] Antigen processing, and presentation [233]	Production of prostaglandins, leukotrienes and proteases [234] Release MIP-1 α and MIP-1 β [235] Release cytokines, such as IFN- γ , IL-8 and TNF- α [71] Secretion of antimicrobial molecules [236] Phagocytosis [237] Release lytic enzymes and producer active oxygen intermediates [71] Release neutrophil extracellular traps (NETs) [71]
Adaptive immunity	Secretion of hydrolytic enzymes [238] Cleavage of C3 [239] Induce neovascularization and contribute to angiogenesis and lymphangiogenesis [240] Modulate the osteoclastogenesis [241] Efferocytosis [242] May induce Th1 cells differentiation [78] Control the effector T-cell homeostasis, promoting the T-cell priming and also may induce Th17 cell differentiation [81]	Release IL-17 [243] Release NETs [71] Promote the maturation of human monocyte-derived DC [88] Chemotaxis of Th1 and Th17 [59, 60] Differentiation of naïve CD8+ T-cells [244]

IFN- γ : interferon gamma; TNF- α : tumour necrosis factor- α ; IL-1 β : interleukin- β ; G-CSF: Granulocyte colony-stimulating factor; GM-CSF: Granulocyte macrophage-colony stimulating factor; MIP-1 α : macrophage inflammatory protein-1 α ; NETs: Neutrophil extracellular traps

tissues homeostasis and development, repair of damaged tissue, rejection of a xenograft, induce angiogenesis and lymphangiogenesis, modulation of osteoclastogenesis, as well as macrophages are key component in elimination of pathogens and removal of dying cells by efferocytosis [5, 78–80]. In addition, resident tissue macrophages also are patrollers in epithelial tissues, ensuring the entry and colonization sites for pathogens in order to prevent the invasion of these infectious agents [80]. An important example is the alveolar macrophages, which keep the lung surface under surveillance-inhaled pathogens [5]. In adaptive immunity, recent studies reported that macrophages may control the effector T-cell homeostasis, promoting the T-cell priming and also inducing Th17 cell differentiation [81]. Also, macrophages modulate cytokine release and T-cell activation, resulting in neuropathic pain [82].

After injury, with or without infection, neutrophils recruited into tissue have an anti-infectious and pro-inflammatory function, due to their ability to phagocyte and to produce powerful components for the host, i.e., ROS, such as O₂⁻, H₂O₂, HOCl, and ·OH; antimicrobial peptides, proteolytic enzymes as serine proteases and metalloproteinase; and release NETs, leading to tissue injury [83–85]. However, recruited neutrophils are mostly removed by DC and macrophages at the site of inflammation by a process of cell corpse removal called efferocytosis [86].

Even though neutrophils are the hallmark effector cells of acute inflammation, these cells also contribute to chronic inflammation and adaptive immune responses, such as cytokines (as IL-17) secreted from neutrophils regulate the immunity by inducing the expression of

pro-inflammatory factors (such as cytokines, chemokines and MMPs) from mesenchymal and myeloid cells, leading to the perpetuation of the recruitment and activation of additional neutrophils in chronic inflammation [87]. In addition, neutrophils directly interact with macrophages, DC, and lymphocyte subsets and modulate their effector functions; as well as promote the maturation of human monocyte-derived DC (moDC) [88]. They interact with DC leading to activation of NK cells and communicate with the B and T-cells and NK cells, as well as cross-interact with NK cells that produce IFN- γ , which promotes survival and activation of the neutrophil [87, 89, 90]. Thus, activated neutrophils secrete chemoattractant, such as CCL2, and CXCL10 or CCL2 and CCL20, which attract and recruit Th1 and Th17 cells, respectively [91, 92]. Neutrophils may express MHC II class and act as APC, thus it migrates to the lymph node attracted to CCR7 [93–95]. Furthermore, the neutrophils can also present exogenous antigens via MHC I class, promoting the differentiation of naïve CD8+ T-cells into cytotoxic T-cells [95]. On the other hand, neutrophils can also compete with the professional APC and thus inhibits the T CD4+ response [95, 96].

Due the ability of neutrophils and macrophages to initiate and control the immune responses against invading pathogens as well as against self-proteins derived peptides, thereby they play an important role in the pathogenesis of autoimmune disorders, such as autoimmune diabetes, rheumatoid arthritis and Systemic Lupus Erythematosus (SLE). However, the nature of the contribution of these cells in autoimmune disorders is not yet fully elucidated, but there are several important factors affecting on the immunogenicity of these cells, including

the type and dose of antigen, the microenvironment of the cell-antigen encounter, the number, the subset, and phenotype of these cells, which can prevent or induce autoimmune responses. In this regard, Orme and Moah [6] reported important alterations of these cells during the establishment of SLE such as: (1) enhanced apoptosis; (2) enhanced chemotaxis due the overexpression of MCP-1, MIP-1 α , CCL5, CXCR4, CXCL12; (3) impaired phagocytosis related to high levels of the complement receptor CR3 (CD11b/ITGAM) and of FC γ R1; (4) impaired immune-complex clearance; (5) and impaired superoxide production.

Overall, most studies indicate that adaptive immunity alone is involved in autoimmune disease. However, other studies have suggested crosstalk between cellular and humoral components involved in the innate and adaptive immune systems, which indicates that the loss of the immune homeostasis between two important pro-inflammatory and anti-inflammatory effectors may trigger the effector phase of autoimmune diseases, as shown in Fig. 4 [97, 98].

Crosstalk between neutrophils/macrophages in autoimmune type 1 diabetes

Autoimmune type 1 diabetes mellitus (T1DM) is a serious chronic autoimmune disease characterized by an absolute insulin deficiency, resulting from an depletion of insulin-secreting β cells located in pancreatic Langerhans' islets mediated by autoantigen-specific CD4(+) and CD8(+) T-lymphocytes promoting further inflammation in this tissue [99–101]. In this regard, innate immune

cells such as $\gamma\delta$ T-cells, NKT, macrophages and neutrophils play essential roles in the pathogenesis of T1DM [102]. These cells produce cytokines that promote β -cell apoptosis and increase infiltration of islet specific T-cells, then this T-cells attack and destroy β -cells, resulting in an insulin deficiency [102].

A lack of insulin results in an inability to regulate blood glucose effectively, leading to chronic hyperglycaemia. Therefore, T1DM may provide a state of hypoinsulinemia and hyperglycaemia, and causes serious health complications including ketoacidosis, kidney failure, heart disease, stroke, and blindness [103]. In diabetes cases, approximately 5–10% of diabetics have T1DM [104], which can be classified into two categories: Type 1A diabetes mellitus, resultant of an autoimmune response destroying the β -cells, while type 1B is an idiopathic destruction of the β -cells [104]. Type 1A diabetes mellitus has a predominantly genetic origin, there are at least 15 loci associated with T1DM, mainly polymorphic genes, such as the human leukocyte antigen (HLA) loci, interleukin 2 receptor alpha (IL2R2), insulin-variable number tandem repeat (VNTR), vitamin D receptor (VDR), cytotoxic T-lymphocyte-associated protein (CTLA)-4 genes [102, 105, 106]. For example, HLA class II haplotypes either DR3DQ2 or DR4DQ8 are express in more than 90% of patients with T1DM [107]. In general, the triggers that initiate the immune-mediated destruction of the β -cells include viruses (Coxsackie B viruses, rubella viruses, cytomegaloviruses and retroviruses), dietary factors (cow's milk, plant proteins, nitrates, wheat gluten) and other environmental factors (e.g., caesarean delivery,




Fig. 4 Major mechanism of action of neutrophils and macrophages in type 1 diabetes and rheumatoid arthritis

early childhood diet, vaccines and use of antibiotics), as well as gut microbes [102, 108].

In addition, hyperglycaemia may be a trigger to inflammatory response in T1DM, because it may increase the levels of circulating C-reactive protein (CRP), free fatty acids, CXCL-8, and pro-inflammatory cytokines, such as IL-6, IL-1 β and TNF- α [109–111]. Hyperglycaemic conditions can also facilitate the activation of human T-lymphocytes [111, 112]. Therefore, the innate immunity plays a critical role in T1DM, because various cells, including macrophages, dendritic cells, NK cells and neutrophils, may recognize pathogens and foreign molecules without having been previously exposed to them and without generating long-term immune response [102].

In acute inflammation, macrophages, mainly the M1 macrophages, are first cells accumulate at one side of the pancreatic islet at an early stage (2–3 weeks of age), along with neutrophils, dendritic cells (DCs) and B lymphocytes [113]. In this regard, M1 macrophages can trigger an inflammation and initiate pancreatic β -cell death and insulinitis during type 1 diabetes [114, 115], as well as it contributes to prolongation of inflammation instead of its resolution [114]. The M1 macrophages are pro-inflammatory cells that responds to intracellular pathogens producers of TNF- α and interleukins (IL-1 β , IL-6, IL-8, IL-12, and IL-23), express costimulatory molecules important in T-cell activation (MHC, CD40, CD86), and produce proteases (leucocyte elastase, and matrix metalloproteinases), such as NO through the expression of iNOS and ROS [116]. Therefore, ROS can induce apoptosis or necrosis of β cells by activating the caspase pathway and inducing excessive cell stress, respectively, because this cell is very sensitive to free radicals and has low free radical scavenging activity [116, 117].

During the chronic inflammation, the IL-12 from M1 macrophages can contribute to destruction of β cells in T1D by directing the development of Th1 cells, with the involvement of CD4+ and CD8+ lymphocytes [118, 119]. Furthermore, activated M1 macrophages have an enhanced ability to present antigen and then stimulate the activation of CD8+ T-lymphocytes, which are directly involved in the destruction of pancreatic β -cells [115, 116, 120]. In animal model, certain studies also pointed to the evidence for initial involvement of macrophage in development of insulinitis in non-obese diabetic (NOD) mice [121, 122]. Other study showed in NOD mice that macrophages from pancreas produced more IL 1 β than peritoneal macrophages [123]. This cytokine production mediates the damage outcome of macrophages on β -cells [124].

However, both macrophages M1 and M2 phenotypes play central role in diabetes.

Similarly, the M2 macrophages phenotypes have also been reported for NOD mice [120, 125] and in human T1D [126, 127]. However, M2 macrophages have distinct functions of M1 macrophages, because the M2 macrophages decrease hyperglycaemia, insulinitis and inflammation in the pancreas [116]. In this regard, the adoptive transfer of immunomodulatory M2 macrophages prevents type 1 diabetes in NOD mice [128]. In short, the characterization of subpopulations of macrophages in diabetes may be useful in designing new strategies to T1DM understanding. Several evidence reported that M2 macrophages secretes anti-inflammatory cytokines IL-4/IL-13 and expresses high levels of PD-1 ligands (Program-Death 1), PDL-1 and PDL-2, thereby this mechanism may inhibit the proliferative response of activated T-cells in T1DM [116].

Regarding to neutrophils, Battaglia [100] highlighted that these cells are crucial in the initiation and perpetuation of T1DM, during acute and chronic inflammation, by two proposed mechanisms: (1) one is due the production of pro-inflammatory cytokines, as IL-17, which promote granulopoiesis and consequent neutrophil proliferation and accumulation, leading to prejudice pancreatic cells; and (2) another involves the unintended entrance of bacteria on pancreas that release toxins, leading to the production of IL-6 and IL-8 that attract neutrophils. Therefore, immune cells in pancreas, especially macrophages and neutrophils are responsible to the initiation and perpetuation of T1DM. Other study reported by Huang et al. [56], showed that several indications suggest the involvement of neutrophils in the initiation and perpetuation of autoimmune diabetes, such as an increased numbers of neutrophils in blood of type 1 diabetes patients, activation and recruitment of neutrophils to pancreatic islets in T1DM patients, liberation of neutrophil toxic mediators and the antineutrophil treatments were able to reduce the insulinitis and autoimmune diabetes.

In this context, in diabetic ketoacidosis patients (DKA) have been found monocytosis and neutrophilia in differential white blood cell count, consistent with previous reports of increased circulation of leukocytes during DKA [129]. Although, there are controversies regarding the exact roles of neutrophils, this cell was found in the pancreas of patients with T1DM, both at the onset and at later stages of the autoimmune process [130]. Some studies have shown an increased adherence of neutrophils to the cerebrovascular endothelium in diabetic ketoacidosis patients [109, 131]. In diabetic ketoacidosis patients were found activated neutrophil with high release of toxic granule content in serum, as elastase, proteinase-3 and myeloperoxidase [132]. Also, patients with T1DM had markedly elevated levels of NE and proteinase 3 (PR3),

which are serine proteases stored in neutrophil primary granules [133]. On the other hand, other studies reported that neutrophils from insulin-dependent diabetics display diminished levels of oxygen radicals (O_2^-) and activation of phospholipase D in response to FMLP, which was attributed to the high glucose concentration in these patients [134]. Also, certain studies have shown that circulating neutrophil number was decreased in patients with T1DM, which may be associated with abnormal neutrophil yield and maturation, peripheral consumption or damage, and tissue detainment [130, 135].

In animal studies, Alba-Loureiro et al. [136] showed that neutrophils from diabetic rats exhibited decreased phagocytosis and phorbol myristate acetate (PMA)-stimulated H_2O_2 production. Similarly, Nurun Nabi et al. [137] reported that neutrophils from diabetic rats were more activated at their basal level, though it exhibited lower morphological polarization in response to FMLP. These authors also demonstrated that an increased plasma glucose level can reduce the phagocytosis of neutrophils from diabetic rats [137]. In addition, Diana et al. [138] observed the occurrence of neutrophils inside the pancreatic infiltrate of NOD mice, but not in non-autoimmune C57BL/6 and BALB/c mice [138]. Another study in NOD mice showed that one of the chemokine receptors that regulates the trafficking of neutrophils to the pancreas is CXCR2, which ligands are produced by pro-IL-1 β secreted by pancreatic macrophages [123]. Thus, the role of neutrophils in T1D started to be elucidated. The presence of neutrophils that secrete cathelicidin-related antimicrobial peptide (CRAMP) was observed in NOD mice histological analysis [138]. In other autoimmune diseases, CRAMP stimulates plasmacytoid dendritic cells (pDCs) to produce IFN- α . Therefore, immune cells in the pancreas, especially macrophages and neutrophils, are responsible for the initiation of T1D.

Together, the current findings indicate that high levels of chemokines, such as CXCL1/KC (or human IL-8) and MCP-1/CCL2, are secreted into the pancreas during T1DM. These chemokines play a key role in the recruitment of neutrophils and macrophages/monocytes, respectively, from the blood vessels to the pancreatic islets [139–141]. In this regard, as shown above, human and animal studies showed that macrophages and neutrophils were found to infiltrate the islet of young NOD mice and T1DM patients, and the inhibition of the influx of these cells into the pancreas, by depletion or inhibiting their adhesion molecules, prevents the development of insulinitis and inflammation in T1DM [114, 130, 142–144]. These facts, taken together, suggest that macrophages are cells important in the stimulation of the influx and activation of cells, including T-cells, which lead to the destruction of the β cells. After starting the inflammatory process, other cells are recruited to the pancreas, such as neutrophils, which

at the beginning of the pathology are involved in the propagation of tissue damage through the release of toxic chemicals. Thus, these findings support the evidence for a crosstalk between macrophages and neutrophils that participate closely in the inflammatory response and progression of the initial pancreatic damage in T1DM.

Crosstalk between neutrophils/macrophages in rheumatoid arthritis

Rheumatoid arthritis (RA) is an inflammatory autoimmune disease characterized as a chronic inflammation within the synovial tissues in multiple joints (synovitis), leading to progressive and erosive destruction of cartilage and joints, and the underlying bones [145]. The pannus formation and synovial hyperplasia are the main features of RA, due to an abundant cellular infiltrate of several cell types (neutrophils, macrophages, fibroblasts, T-cells, and dendritic cells) in the synovium [146, 147]. Furthermore, the aetiology and pathogenesis of RA have not been completely elucidated, but it is widely accepted that it is a multifactorial disease associated with genetic factors (HLA genes, as HLA-DRw4 and HLA-DRB1, PTPN22 (encoding tyrosine-protein phosphatase non-receptor type 22) gene, protein-arginine deiminase type 4 (PADI4) gene and cytotoxic T-lymphocyte protein 4 (CTLA-4) gene), environmental (e.g., cigarette smoke), gender and age [148–150]. In this context, certain studies report potential roles for sex hormones and sex chromosomes in the induction of RA [151, 152].

Furthermore, environmental factors may lead to molecular changes to host proteins, followed by a breakdown of immune tolerance to self, thereby increasing the risk of developing RA in individuals with genetic risk factors [153]. Certain environmental exposures induce peptidyl arginine deiminase (PAD) enzyme activation and consequently protein citrullination [154, 155] that in turn lead to the development of autoantibodies to citrullinated protein antigens (ACPAs), which are detected in RA patients' serum [156]. ACPAs are directed against different citrullinated antigens, including fibrinogen, fibronectin, α -enolase, collagen type II, histones. Furthermore, these antibodies are detected years before the onset of clinical arthritis and are associated with joint radiographic damage and extra-articular manifestations [157]. In RA, there are many cell types that play a role in the pathogenesis, such as fibroblasts, T-lymphocytes, B lymphocytes, neutrophils and macrophages [158]. It is known that there is an imbalance between pro and anti-inflammatory cytokines that can be a key mechanism underlying disease progression in collagen-induced arthritis (CIA) mice model as well as in human RA [159].

In this context, neutrophils are the first effector cells at the site of inflammation, mainly in the initiation of

various pathologies including chronic inflammatory diseases. Thereby, these cells play a key role in the tissue damage and facilitate the inflammatory process in RA, leading to joint destruction in arthritis models [160, 161]. In animal models studies, the neutrophil depletion with antibodies blocked or reversed the joint swelling and joint inflammation in arthritis [162]. In addition, neutrophils are the most abundant both in the synovial fluid (SF) and pannus of patients with active RA. Chemoattractants such as G-CSF and IL-8 stimulate neutrophil migration from the peripheral blood to the joint in RA [163], as well as promotes neutrophil trafficking into inflamed joints [164]. In this context, some studies showed that neutrophils from RA patients are functionally different from those of healthy individuals, because they have delayed apoptosis and are more susceptible to stimulation via TLRs and receptors for complement fragments, growth factors, cytokines and immune complexes [165–168].

Once activated, in acute inflammation of RA, neutrophils release high concentrations of oxidants and cytotoxic products, such as ROS, cytokine (such as TNF- α) and granules containing proteases, phospholipases, defensins and myeloperoxidase, in the synovial fluid or directly onto the surface of articular cartilage [166, 167, 169]. Moreover, Wright et al. [156] summarized the relevant role of certain neutrophil granule enzymes found in high concentrations in RA synovial fluid, such as contributes to the destruction of the articular cartilage and tissue (e.g., elastase, gelatinase and collagenase), promotes inflammation and activate cytokines/receptors (e.g., elastase, cathepsin G, proteinase 3 and lactoferrin), as well as inhibits resolution of chronic inflammation and cartilage repair (e.g., myeloperoxidase and gelatinase-associated lipocalin). In addition, other effects also were described, including inhibit chondrocyte apoptosis (e.g., lactoferrin), and regulating migration, invasion and proliferation of synoviocytes (e.g., cathepsin and matrix metalloproteinases) [170–176].

In chronic inflammation of RA, several studies have linked neutrophil functions to Th17 cells. These cells are producers of IL-17 that is a potent pro-inflammatory mediator implicated in the pathogenesis of RA, involved in induction of tissue inflammation by stimulating the recruitment of neutrophils. In the RA joint, IL-17 also activates fibroblast-like synoviocytes, macrophages, and osteoblasts [91, 92, 177]. Thus, these activated cells in the joint produce potent neutrophil chemoattractants, as IL-8 and TNF- α , which in combination with IL-17 stimulate synovial endothelial cells to produce more neutrophil chemoattractants [91, 92, 177]. Thereby, neutrophils found in the RA joint help sustain Th17 cells through the secretion of Th17 chemokines, as CCL20 and CCL2 [91,

92]. In addition, synovial fluid and peripheral blood neutrophils from patients with osteoarthritis are more likely to form NETs than in neutrophils from healthy controls [177]. In this regard, NETs also are source of citrullinated protein, as such histone and vimentin, because during NETosis occurs hypercitrullination of histones induced by the enzyme peptidyl arginine deiminase type 4 (PAD4) [178]. The ACPAs in the serum of patients with RA react with histone H4 in the NETs [179] and are correlated with disease activity and the severity of joint destruction [153]. Indeed, RA serum, anti-antibodies, as well as inflammatory cytokines IL17A and TNF, induce NETosis in RA neutrophils [180]. Overexpression of IL-17A in healthy mouse knee joints induced rheumatoid arthritis (RA)-like pathology with features including joint inflammation, focal bone erosion and cartilage damage [181]. In fact, NETosis is enhanced in circulating and synovial fluid neutrophils from patients with RA and it was observed NETs infiltrated in RA synovial tissue, rheumatoid nodules, and skin, mainly in patients with high levels of ACPA. In addition, NETs enhance inflammatory responses in RA synovial fibroblasts by stimulating production of IL-8 that may further enhance NETosis [182], citrullinated autoantigen exposure, and promote autoantibody generation amplifying mechanism of joint damage [183]. In conclusion, NETs externalize various immunostimulatory molecules and citrullinated auto 1 antigens that, in predisposed individuals might account for persistent generation of ACPA.

Therefore, in summary, there is strong evidence that the neutrophils have multiple functions in regulating acute and chronic inflammation in RA, such as: (1) produce mediators, such as IL-10, IL-1 receptor antagonist (IL-1ra) and TGF- β , with play an important anti-inflammatory role during both acute and chronic microbial infections or that contribute to resolution of inflammation; (2) secrete pro-inflammatory and anti-inflammatory cytokines and chemokines that regulate the function of immune cells (e.g., active macrophages, promote activation, proliferation and differentiation of T-lymphocytes, recruitment and maturation of dendritic cells) [156, 184, 185]; (3) Human neutrophils express MHC class II (HLA-DR) and co-stimulatory molecules (e.g., CD80 and CD86) that stimulate superantigen-dependent T-lymphocytes activation, as well promote differentiation of the Th1 and Th17 effector T-cell subsets [94, 186–188]; (4) Activated neutrophils express the B cell-activating cytokine (BLyS or BAFF) and the interaction between neutrophils and marginal zone B cells mediate T-cell-independent antibody responses through BAFF and a proliferation-inducing ligand (APRIL) [189–193]; (5) Neutrophils play a role in regulating the homeostasis; terminal differentiation and functional responsiveness of NK cells in human and mice, as well as neutrophil-derived mediators modulate

NK cell effector functions, possibly in close relationship with dendritic cells [88, 156, 193]. Other functions also were reported, as synovial fluid neutrophils of patients with exacerbation of RA strongly express receptor activator of nuclear factor kappa-B ligand (RANKL) that activate the osteoclastogenesis [166, 194], while peripheral blood neutrophils from both RA patients express B lymphocyte stimulator (BLyS or BAFF), which is implicated in regulation of B cell-dependent autoimmunity [195].

Macrophages are one of the resident cell types in synovial tissue, along with fibroblasts [196]. In the context, once activated macrophages have a critical role in RA in chronic inflammatory arthritis and these cells have high plasticity, differentiating into different phenotypes, which can secrete either pro-inflammatory (M1 macrophages) or anti-inflammatory (M2 macrophages) cytokines [46, 197]. Both macrophages types are important to mediate matrix destruction or deposition, as well as help to resolution of inflammation [44, 196, 198]. During the last years, several studies have found greater numbers of M1 macrophages in synovial membranes of patients with RA and its depletion using specific antibodies can prevent their presence in the pannus and thus attenuate inflammation [199–201]. In addition, monocytes/macrophages are also associated with pathological bone erosion on RA, because these cells differentiate into osteoclasts, specialized cells in bone resorption [202].

Overall, synovial macrophages may stimulate the angiogenesis, leukocyte and lymphocyte recruitment, fibroblast proliferation, and protease secretion leading to eventual joint destruction [203–205]. M1 macrophages have around 30–40% of the cellular content, and secrete pro-inflammatory cytokines (TNF α , IL-1, IL-6, IL-12, IL-23, and low levels of IL-10) and enzymes involved in driving the acute inflammatory response and joint destruction [196]. In addition, high levels of pro-inflammatory cytokines and chemokines also contribute to the cartilage and bone destruction, and in the pannus formation in RA [119]. In this context, chemokines released by M1 macrophages promote the recruitment of leukocytes to the inflamed joint, which produce more pro-inflammatory mediators as IL-1, TNF- α , IL-6 and matrix metalloproteinase leading a destructive potential synovial and bone, mainly in osteoarthritis [147]. Therefore, the IL-1 and TNF- α are the most abundant cytokines in the inflamed synovium, leading to synovial inflammation and activate chondrocytes and synovial fibroblasts. Thus, these cells produce IL-6, IL-8, and leukocyte inhibitory factor, as well as stimulate protease and prostaglandin production in synovia [206–208]. In addition, IL-1 and TNF- α also induce the expression of other cytokines (e.g., IFN γ), cell-adhesion molecules, chemokines and chemokine receptors, antigenic

factors and lipid mediators and inducible nitric oxide synthase (iNOS) in the inflammatory site [41, 196]. The TNF α and other molecules also induce the histone acetyltransferase (HAT) activity in macrophages, leading the acetylation of histones and subsequent modulation of transcriptional factors [196]. The IFN γ is another cytokine highly expressed in RA synovial tissue and its elevated levels correlates with RA severity [209]. In this context, pro-inflammatory cytokines, like TNF α , can upregulate the production of IFN γ that increase the response of M1 macrophages, while IL-10, anti-inflammatory cytokines downregulate this effect [210, 211]. Therefore, Wallet et al. [211] showed that IFN γ -primed activated macrophages produced elevated levels of TNF α and other TH1 cytokines, as IL-12p70, but not of regulatory cytokine, as IL-10. Regarding to IL-10, Ji et al. [212] reported that in RA occurs a suppression of IL-10 signal transduction by blocking the FC γ receptor ligation induced by the combination of IFN and immune complexes found in RA, thereby a dysregulation of IL-10 signalling by these factors contribute to pathogenesis of RA.

On the other hand, M2 macrophages, during chronic inflammation, produce anti-inflammatory cytokines that is associated with tissue remodelling and immunoregulatory functions, improving the pathogenesis of RA [196, 212]. Thereby, the inhibition of macrophages should be a strategy of inhibiting inflammation and bone erosion in arthritis. Thus, the switch from a pro-inflammatory phenotype (M1) to an anti-inflammatory state (M2) can contribute to ameliorate the disease. Their plasticity makes them a target for the treatment of inflammation, especially arthritis. In this regard, certain studies reported that M2 macrophages profile is involved in spondyloarthritis (SpA) pathogenesis compared to RA patients, while M1 mediators correlate with joint inflammation in RA [213]. Therefore, Ambarus et al. [200] reported increased number of CD163+ macrophage (M2) phenotype in spondyloarthritis (SpA) synovitis, but not in RA, as well as these authors showed lower levels of M1-derived cytokines (pro-inflammatory) in SpA compared with RA synovial fluid. Therefore, certain studies have used M2 polarizing cytokines like IL-10 as therapy target, showing that IL-10-treated animals exhibited suppression of the development and progression of joint inflammation, even in established disease [214–216].

Moreover, other studies reported a possible key for macrophages in RA development in part by successful treatment of RA by anti-TNF antibodies [217–219]. The block TNF- α resulted in the inhibition of IL-1 β , IL-6 and IL-8 production [220–222]. Also, in RA, high levels of IL-17 and its receptor are found in RA synovial fluid and tissues [223]. In this context, researchers have suggested that the IL-23/IL-17 pathway, rather than the

IL-12–IFN- γ axis, is essential to promoting the development of CIA [224]. Indeed, the IL-10 inhibits IL-17 and ROR γ t expression in macrophages and suppresses macrophages toward the pro-inflammatory M1 phenotype, which is important for the role of IL-10 in mediating the pathogenesis of CIA [225, 226]. In addition, M1 macrophages have the ability to drive the CD4+ T helper cell polarization; thereby it can trigger B-cell and production of immunoglobulins and rheumatoid factor in synovia [227, 228].

These findings reveal a crosstalk between neutrophils and macrophages, which may result in a cascade of reactions leading to the destruction of host tissues, mainly during inflammation chronic, associated with RA. In short, after the initiating event, neutrophils are one of the first cells attracted to the site of inflammation, which together with synovial macrophages or recruited release ROS, cytokines, chemotactic factors, and granules enzymes, such as collagenases, proteinases, and elastases, accentuating the inflammatory response that result in cell damage in the synovial fluid of the joints during the RA. Neutrophil death or degranulation or formation of NETs may result in the release of soluble products into the extracellular environment where are scavenged by macrophages. In addition, neutrophils and macrophages

participate in the regulation and activation of other cell types such as T and B lymphocytes, dendritic cells, NK cells. Thus, our data suggest that mechanisms involving these cells and their mediators can be important for understanding both the pathology and possible therapeutic interventions for RA.

Concluding remarks and future directions

As described in this review, neutrophils and macrophages share the same origin and also have a number of common functions (e.g., pathogens phagocytosis, similar kinetic behaviour during the process of inflammation and immunomodulatory properties). Furthermore, it is well elucidated that neutrophils and macrophages are important cells of both the innate and acquired immune response to fight infectious agents. However, products released by these cells during the inflammatory process can also recruit and/or activate other cell types such as epithelial cells, endothelial cells, platelets, T and B lymphocytes, NK cells, among others. Thus, these factors set contribute effectively to the development of several autoimmune diseases such as rheumatoid arthritis and diabetes and others, as well as discussed in this review.

Nonetheless, neutrophils have an important role recruiting and activating macrophages to the site of





Fig. 5 A simplified schematic of the crosstalk between neutrophils/macrophages in rheumatoid arthritis

infection or acute inflammation. Therefore, the interaction of neutrophils and macrophages is a key event in innate immune response in the autoimmune diseases. In summary, during the inflammatory process, macrophages migrate at the same time or after the influx of neutrophils into the inflamed tissue, taking a direct or indirect interaction between these cells. As previously reported, macrophages of profile M1 secrete TNF- α , and along with neutrophils contribute to local inflammation, while M2 secrete IL-4 and IL-10 that modulate the inflammation, improving the tissue damage. Moreover, M1 macrophages are generated starting from cellular immune responses, and vital to the defence of the host. However, an exaggerated activation of these cells can lead to tissue damage as it is seen in many chronic inflammatory and autoimmune diseases, including type 1 diabetes, rheumatoid arthritis and others. In this regards, neutrophils can release NETs, molecules that are associated the induction of several autoimmune diseases, due they acted

as auto-antigen, as well as the excessive formation or degradation failure of these NETs can lead the auto-antigens expression and danger-associated molecular patterns. Furthermore, neutrophils can migrate to lymph nodes and to regulate the functions of macrophages/DC, leading to cross-presentation antigens to T-cells. In addition, neutrophils can express MHC class II and co-stimulatory molecules that directly to activate superantigen-dependent T-lymphocytes and help the differentiation of the Th1 and Th17 effector T-cell subsets. Also, activated neutrophils may express the BLYS or BAFF that mediate the T-cell-independent antibody responses of these cytokines, and then cooperating to activation of the adaptive immune responses. Thereby, many studies corroborate with the knowledge that neutrophils and macrophages, during infection and autoimmune diseases, play an important role in regulating of both T and B cells and activating other immune mechanisms, as shown in Fig. 5.



However, the major limitation currently facing these studies is the lack of studies that relate the functions in sets of cells involved in the pathogenesis of autoimmune diseases. This is likely due to the complexity of measuring the interactions among neutrophils and macrophages and their mediators that are involved in these disorders. Most studies focus on these characteristics of a targeted cell or molecule under *in situ* conditions. Important questions thus persist regarding, for instance, how to relate the plasticity and diversity of macrophages and neutrophils, which are quite important in mediating the innate and adaptive immune responses leading to tissue damage in type 1 diabetes and rheumatoid arthritis, as well as how these factors may help to develop multiple interventions that address the inflammatory responses and tolerogenic roles of these cells in these diseases, as shown in Fig. 6. However, future studies might examine whether therapeutic interventions that simultaneously modulate certain roles of macrophages and neutrophils can also improve of symptoms and prevent organ damage in autoimmune diseases. These findings remain to be clarified in order to elucidate the immune mechanisms involving several cell types and soluble factors released to injured tissue.

Abbreviations

GCSF: granulocyte colony-stimulating factor; MYPs: myeloid phagocyte system; SDF-1: stromal derived factor-1; CXCR: C-X-C motif chemokine receptor; LXR: liver X receptor; IL: interleukin; MPS: mononuclear phagocyte system; M-CSF: macrophage-colony stimulating factor; Csf1: hematopoietic growth factor receptor; DC: dendritic cells; HSCs: hematopoietic stem cells; LPS: lipopolysaccharides; IFN: interferon; NK: natural killer; SOCS3: suppressor of cytokine signalling 3; TLR: toll-like receptor; TGF: transforming growth factor; ROS: reactive oxygen species; NETs: neutrophil extracellular traps; NE: neutrophil elastase; MPO: myeloperoxidase; BPI: bactericidal permeability increasing protein; MMP-9: matrix metalloproteinase-9; PAD4: peptidyl arginine deiminase 4; APC: antigen-presenting cells; T1DM: autoimmune type 1 diabetes mellitus; HLA: human leukocyte antigen; IL2R2: interleukin 2 receptor alpha; VNTR: insulin-variable number tandem repeat; VDR: vitamin D receptor; CTLA: cytotoxic T-lymphocyte-associated protein; CRP: C-reactive protein; PR3: proteinase 3; PMA: phorbol myristate acetate; CRAMP: cathelicidin-related antimicrobial peptide; RA: rheumatoid arthritis; PAD14: protein-arginine deiminase type 4; PAD: peptidyl arginine deiminase; ACPAs: autoantibodies to citrullinated protein antigens; CIA: collagen-induced arthritis; SF: synovial fluid.

Authors' contributions

All authors participated in the design of the study and drafted the manuscript. MCM participated in the study coordination and helped to draft the manuscript. KCN have designed and prepared the manuscript figures. All authors read and approved the final manuscript.

Author details

¹ Pharmaceutical Science Post-Graduation Program, Health Science Institute, Federal University of Pará/UFPA, Belém, PA 66075900, Brazil. ² Department of Clinical, Bromatological and Toxicological Analysis, Ribeirão Preto Pharmaceutical Sciences School, USP-SP, Ribeirão Preto, SP, Brazil. ³ College of Pharmacy, Guairacá Faculty-PR, Guarapuava, PR, Brazil.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

The datasets supporting the conclusions of this article are included within the article.

Funding

The authors were supported by the Brazilian's agencies: Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação Amazônia Paraense de Amparo à Pesquisa (FAPESPA), Federal University of Pará and MCM thanks for the fellowship from CNPq.

Received: 18 November 2016 Accepted: 3 February 2017

Published online: 15 February 2017

References

- Henderson RB, Hobbs JAR, Mathies M, Hogg N. Rapid recruitment of inflammatory monocytes is independent of neutrophil migration. *Blood*. 2003;102:328–35.
- Duffield JS. The inflammatory macrophage: a story of Jekyll and Hyde. *Clin Sci*. 2003;104:27–38.
- Rosenblum MD, Remedios KA, Abbas AK. Mechanisms of human autoimmunity. *J Clin Invest*. 2015;125:2228–33.
- Perobelli SM, Galvani RG, Goncalves-Silva T, Xavier CR, Nobrega A, Bonomo A. Plasticity of neutrophils reveals modulatory capacity. *Braz J Med Biol Res*. 2015;48:665–75.
- Weiss G, Schaible UE. Macrophage defense mechanisms against intracellular bacteria. *Immunol Rev*. 2015;264:182–203. <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4368383&tool=pmcentrez&rendertype=abstract>.
- Orme J, Mohan C. Autoimmunity reviews macrophages and neutrophils in SLE—an online molecular catalog. *Autoimmun Rev*. 2012;11:365–72.
- Silva MT, Correia-Neves M. Neutrophils and macrophages: the main partners of phagocyte cell systems. *Front Immunol*. 2012;3:174. <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3389340&tool=pmcentrez&rendertype=abstract>.
- Metcalf D. Hematopoietic cytokines. *Blood*. 2008;111:485–91.
- Richards MK, Liu F, Iwasaki H, Akashi K, Link DC. Pivotal role of granulocyte colony-stimulating factor in the development of progenitors in the common myeloid pathway. *Blood*. 2003;102:3562–8.
- Liu F, Wu HY, Wesselschmidt R, Kornaga T, Link DC. Impaired production and increased apoptosis of neutrophils in granulocyte colony-stimulating factor receptor-deficient mice. *Immunity*. 1996;5:491–501.
- Tan BH, Meinken C, Bastian M, Bruns H, Legaspi A, Ochoa MT, et al. Macrophages acquire neutrophil granules for antimicrobial activity against intracellular pathogens. *J Immunol*. 2006;177:1864–71. <http://www.jimmunol.org/cgi/doi/10.4049/jimmunol.177.3.1864>.
- Chow A, Brown BD, Merad M. Studying the mononuclear phagocyte system in the molecular age. *Nat Rev Immunol*. 2011;11:788–98. doi:10.1038/nri3087.
- von Vietinghoff S, Ley K. Homeostatic regulation of blood neutrophil counts. *J Immunol*. 2008;181:5183–8. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2745132/>.
- Kruger P, Saffarzadeh M, Weber ANR, Rieber N, Radsak M, von Bernuth H, et al. Neutrophils: between host defence, immune modulation, and tissue injury. In: Dehio C editor. *PLoS Pathog*, vol 11. San Francisco: Public Library of Science; 2015. e1004651. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4357453/>.
- Summers C, Rankin SM, Condliffe AM, Singh N, Peters AM, Chilvers ER. Neutrophil kinetics in health and disease. *Trends Immunol*. 2010;31:318–24. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2930213/>.
- Jonsson F, Mancardi DA, Albanesi M, Bruhns P. Neutrophils in local and systemic antibody-dependent inflammatory and anaphylactic reactions. *J Leukoc Biol*. 2013;94:643–56.
- Burdon PCE, Martin C, Rankin SM. Migration across the sinusoidal endothelium regulates neutrophil mobilization in response to ELR + CXC chemokines. *Br J Haematol*. 2008;142:100–8.

18. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al. Neutrophil extracellular traps kill bacteria. *Science*. 2004;303:1532–5.
19. Eash KJ, Greenbaum AM, Gopalan PK, Link DC. CXCR2 and CXCR4 antagonistically regulate neutrophil trafficking from murine bone marrow. *J Clin Invest*. 2010;120:2423–31. doi:[10.1172/JCI41649](https://doi.org/10.1172/JCI41649).
20. Kroemer G, El-Deiry WS, Golstein P, Peter ME, Vaux D, Vandenberg P, et al. Classification of cell death: recommendations of the Nomenclature Committee on cell death. *Cell Death Differ*. 2005;12(Suppl 2):1463–7.
21. Mevorach D, Trahtemberg U, Krispin A, Attalah M, Zazoun J, Tabib A, et al. What do we mean when we write “senescence”, “apoptosis”, “necrosis”, or “clearance of dying cells”? *Ann NY Acad Sci*. 2010;1209:1–9.
22. Averbhoff P, Kolbe M, Zychlinsky A, Weinrauch Y. Single residue determines the specificity of neutrophil elastase for *Shigella* virulence factors. *J Mol Biol*. 2008;377:1053–66.
23. A-Gonzalez N, Bensinger SJ, Hong C, Beceiro S, Bradley MN, Zelcer N, et al. Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. *Immunity*. 2009;31:245–58.
24. Gerhardt T, Ley K. Monocyte trafficking across the vessel wall. *Cardiovasc Res*. 2015;107:321–30.
25. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages and dendritic cells. *Science*. 2010;327:656–61. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2887389/>.
26. Sasmono RT, Oceandy D, Pollard JW, Tong W, Pavli P, Wainwright BJ, et al. A macrophage colony-stimulating factor receptor-green fluorescent protein transgene is expressed throughout the mononuclear phagocyte system of the mouse. *Blood*. 2003;101:1155–63.
27. Hashimoto D, Chow A, Noizat C, Teo P, Beasley MB, Leboeuf M, et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. *Immunity*. 2013;38:792–804.
28. Epelman S, Lavine KJ, Randolph GJ. Origin and functions of tissue macrophages. *Immunity*. 2014;41:21–35. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470379/>.
29. Epelman S, Lavine KJ, Beaudin AE, Sojka DK, Carrero JA, Calderon B, et al. Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation. *Immunity*. 2016;40:91–104. doi:[10.1016/j.immuni.2013.11.019](https://doi.org/10.1016/j.immuni.2013.11.019).
30. Tanaka Y, Hayashi M, Kubota Y, Nagai H, Sheng G, Nishikawa S-I, et al. Early ontogenic origin of the hematopoietic stem cell lineage. *Proc Natl Acad Sci USA*. 2012;109:4515–20.
31. Orkin SH, Zon LI. Hematopoiesis: an evolving paradigm for stem cell biology. *Cell*. 2008;132:631–44.
32. Okabe Y, Medzhitov R. Tissue-specific signals control reversible program of localization and functional polarization of macrophages. *Cell*. 2014;157:832–44.
33. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. *F1000Prime Rep*. 2014;6:1–13. <http://www.f1000.com/prime/reports/b/6/13>.
34. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. *Immunity*. 2014;41:14–20.
35. Guillemins M, Ginhoux F, Jakubzick C, Naik SH, Onai N, Schraml BU, et al. Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. *Nat Rev Immunol*. 2014;14:571–8. doi:[10.1038/nri3712](https://doi.org/10.1038/nri3712).
36. Dale DC, Boxer L, Liles WC. The phagocytes: neutrophils and monocytes. *Blood*. 2008;112:935–45.
37. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. *Nature*. 2013;496:445–55. doi:[10.1038/nature12034](https://doi.org/10.1038/nature12034).
38. Chinetti-Gbaguidi G, Colin S, Staels B. Macrophage subsets in atherosclerosis. *Nat Rev Cardiol*. 2015;12:10–7. doi:[10.1038/nrcardio.2014.173](https://doi.org/10.1038/nrcardio.2014.173).
39. Liu Y-C, Zou X-B, Chai Y-F, Yao Y-M. Macrophage polarization in inflammatory diseases. *Int J Biol*. 2014;10:520–9.
40. Jansen A, Homo-Delarche F, Hooijkaas H, Leenen PJ, Dardenne M, Drexhage HA. Immunohistochemical characterization of monocytes-macrophages and dendritic cells involved in the initiation of the insulinitis and beta-cell destruction in NOD mice. *Diabetes*. 1994;43:667–75.
41. Furlan R, Cuomo C, Martino G. Animal models of multiple sclerosis. *Methods Mol Biol*. 2009;549:157–73.
42. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastlein RA, et al. Divergent pro- and anti-inflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. *J Exp Med*. 2003;198:1951–7.
43. Smith AM, Rahman FZ, Hayee B, Graham SJ, Marks DJB, Sewell GW, et al. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn’s disease. *J Exp Med*. 2009;206:1883–97.
44. Kraakman MJ, Murphy AJ, Jandeleit-Dahm K, Kammoun HL. Macrophage polarization in obesity and type 2 diabetes: weighing down our understanding of macrophage function? *Front Immunol*. 2014;5:470. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176397/>.
45. Kinne RW, Bräuer R, Stuhlmüller B, Palombo-Kinne E, Burmester G-R. Macrophages in rheumatoid arthritis. *Arthritis Res*. 2000;2:189–202. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC130001/>.
46. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. *Trends Immunol*. 2002;23:549–55.
47. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. *Trends Immunol*. 2004;25:677–86.
48. Satoh T, Takeuchi O, Vandenbon A, Yasuda K, Tanaka Y, Kumagai Y, et al. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. *Nat Immunol*. 2010;11:936–44.
49. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. *Immunity*. 2015;32:593–604. doi:[10.1016/j.immuni.2010.05.007](https://doi.org/10.1016/j.immuni.2010.05.007).
50. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. *Nat Rev Immunol*. 2005;5:953–64.
51. David S, Kroner A. Repertoire of microglial and macrophage responses after spinal cord injury. *Nat Rev Neurosci*. 2011;12:388–99.
52. Junttila IS, Mizukami K, Dickensheets H, Meier-Schellersheim M, Yamane H, Donnelly RP, et al. Tuning sensitivity to IL-4 and IL-13: differential expression of IL-4Ralpha, IL-13Ralpha1, and gammaC regulates relative cytokine sensitivity. *J Exp Med*. 2008;205:2595–608.
53. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. *F1000Prime Rep*. 2014;6:13. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3944738/>.
54. Anderson CF, Mosser DM. A novel phenotype for an activated macrophage: the type 2 activated macrophage. *J Leukoc Biol*. 2002;72:101–6.
55. Hao N-B, Lü M-H, Fan Y-H, Cao Y-L, Zhang Z-R, Yang S-M. Macrophages in tumor microenvironments and the progression of tumors. *Clin Dev Immunol*. 2012;2012:1–11. <http://www.pubmed-central.nih.gov/articlerender.fcgi?artid=3385963&tool=pmcentrez&endertype=abstract>.
56. Sabat R, Grutz G, Warszawska K, Kirsch S, Witte E, Wolk K, et al. Biology of interleukin-10. *Cytokine Growth Factor Rev*. 2010;21:331–44.
57. Huang J, Xiao Y, Xu A, Zhou Z. Neutrophils in type 1 diabetes. *J Diabetes Investig*. 2016. doi:[10.1111/jdi.12469](https://doi.org/10.1111/jdi.12469).
58. Hong C, Kidani Y, A-Gonzalez N, Phung T, Ito A, Rong X, et al. Coordinate regulation of neutrophil homeostasis by liver X receptors in mice. *J Clin Invest*. 2012;122:337–47. <http://www.jci.org/articles/view/58393>.
59. Parker H, Albrett AM, Kettle AJ, Winterbourn CC. Myeloperoxidase associated with neutrophil extracellular traps is active and mediates bacterial killing in the presence of hydrogen peroxide. *J Leukoc Biol*. 2012;91:369–76.
60. Bianchi M, Niemiec MJ, Siler U, Urban CF, Reichenbach J. Restoration of anti-*Aspergillus* defense by neutrophil extracellular traps in human chronic granulomatous disease after gene therapy is calprotectin-dependent. *J Allergy Clin Immunol*. 2011;127:1243.e7–1252.e7.
61. Fuchs TA, Abed U, Goosmann C, Hurwitz R, Schulze I, Wahn V, et al. Novel cell death program leads to neutrophil extracellular traps. *J Cell Biol*. 2007;176:231–41.
62. Papayannopoulos V, Metzler KD, Hakkim A, Zychlinsky A. Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. *J Cell Biol*. 2010;191:677–91.

63. Cui B-B, Tan C-Y, Schorn C, Tang H-H, Liu Y, Zhao Y. Neutrophil extracellular traps in sterile inflammation: the story after dying? *Autoimmunity*. 2012;45:593–6.
64. Neeli I, Dwivedi N, Khan S, Radic M. Regulation of extracellular chromatin release from neutrophils. *J Innate Immun*. 2009;1:194–201.
65. Wang Y, Li M, Stadler S, Correll S, Li P, Wang D, et al. Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation. *J Cell Biol*. 2009;184:205–13.
66. Hakkim A, Furnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. *Proc Natl Acad Sci USA*. 2010;107:9813–8.
67. Villanueva E, Yalavarthi S, Berthier CC, Hodgins JB, Khandpur R, Lin AM, et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. *J Immunol*. 2011;187:538–52.
68. Kessenbrock K, Krumbholz M, Schonermarck U, Back W, Gross WL, Werb Z, et al. Netting neutrophils in autoimmune small-vessel vasculitis. *Nat Med*. 2009;15:623–5.
69. Unanue ER. The regulation of lymphocyte functions by the macrophage. *Immunol Rev*. 1978;40:227–55.
70. Hachicha M, Naccache PH, McColl SR. Inflammatory microcrystals differentially regulate the secretion of macrophage inflammatory protein 1 and interleukin 8 by human neutrophils: a possible mechanism of neutrophil recruitment to sites of inflammation in synovitis. *J Exp Med*. 1995;182:2019–25.
71. Borregaard N. Neutrophils, from marrow to microbes. *Immunity*. 2010;33:657–70.
72. Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. *Nat Rev Immunol*. 2011;11:519–31.
73. Amulic B, Cazalet C, Hayes GL, Metzler KD, Zychlinsky A. Neutrophil function: from mechanisms to disease. *Annu Rev Immunol*. 2012;30:459–89.
74. Rao X, Zhong J, Sun Q. The heterogenic properties of monocytes/macrophages and neutrophils in inflammatory response in diabetes. *Life Sci*. 2014;116:59–66.
75. Ryan GB, Majno G. Acute inflammation. A review. *Am J Pathol*. 1977;86:183–276. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2032041/>.
76. Petrofsky M, Bermudez LE. Neutrophils from *Mycobacterium avium*-infected mice produce TNF- α , IL-12, and IL-1 β and have a putative role in early host response. *Clin Immunol*. 1999;91:354–8.
77. Beauvillain C, Delneste Y, Scotet M, Peres A, Gascan H, Guermonprez P, et al. Neutrophils efficiently cross-prime naive T cells in vivo. *Blood*. 2007;110:2965–73.
78. Martin CJ, Booty MG, Rosebrock TR, Nunes-Alves C, Desjardins DM, Keren I, et al. Efferocytosis is an innate antibacterial mechanism. *Cell Host Microbe*. 2012;12:289–300.
79. Laskin DL, Sunil VR, Gardner CR, Laskin JD. Macrophages and tissue injury: agents of defense or destruction? *Annu Rev Pharmacol Toxicol*. 2011;51:267–88.
80. Varricchi G, Granata F, Loffredo S, Genovese A, Marone G. Angiogenesis and lymphangiogenesis in inflammatory skin disorders. *J Am Acad Dermatol*. 2015;73:144–53.
81. Muraile E, Leo O, Moser M. TH1/TH2 paradigm extended: macrophage polarization as an unappreciated pathogen-driven escape mechanism? *Front Immunol*. 2014;5:603.
82. Arnold CE, Gordon P, Barker RN, Wilson HM. The activation status of human macrophages presenting antigen determines the efficiency of Th17 responses. *Immunobiology*. 2015;220:10–19. <http://www.science-direct.com/science/article/pii/S0171298514001910>.
83. Kobayashi Y, Kiguchi N, Fukazawa Y, Saika F, Maeda T, Kishioka S. Macrophage-T cell interactions mediate neuropathic pain through the glucocorticoid-induced tumor necrosis factor ligand system. *J Biol Chem*. 2015;290:12603–13.
84. Lerman YV, Kim M. Neutrophil migration under normal and sepsis conditions. *Cardiovasc Hematol Disord Drug Targets*. 2015;15:19–28.
85. Doring Y, Drechsler M, Soehnlein O, Weber C. Neutrophils in atherosclerosis: from mice to man. *Arterioscler Thromb Vasc Biol*. 2015;35:288–95.
86. Nowarski R, Gagliani N, Huber S, Flavell RA. Innate immune cells in inflammation and cancer. *Cancer Immunol Res*. 2013;1:77–84. <http://cancerimmunolres.aacrjournals.org/cgi/doi/10.1158/2326-6066.CIR-13-0081>.
87. Ravichandran KS. Find-me and eat-me signals in apoptotic cell clearance: progress and conundrums. *J Exp Med*. 2010;207:1807–17.
88. Ferretti S, Bonneau O, Dubois GR, Jones CE, Trifileff A. IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger. *J Immunol*. 2003;170:2106–12.
89. Jaillon S, Galdiero MR, Del Prete D, Cassatella MA, Garlanda C, Mantovani A. Neutrophils in innate and adaptive immunity. *Semin Immunopathol*. 2013;35:377–94.
90. Costantini C, Micheletti A, Calzetti F, Perbellini O, Pizzolo G, Cassatella MA. Neutrophil activation and survival are modulated by interaction with NK cells. *Int Immunol*. 2010;22:827–38.
91. Jaeger BN, Donadieu J, Cognet C, Bernat C, Ordonez-Rueda D, Barlogis V, et al. Neutrophil depletion impairs natural killer cell maturation, function, and homeostasis. *J Exp Med*. 2012;209:565–80.
92. Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. *Nat Rev Immunol*. 2010;10:479–89. doi:10.1038/nri2800.
93. Costantini C, Calzetti F, Perbellini O, Micheletti A, Scarponi C, Lonardi S, et al. Human neutrophils interact with both 6-sulfo LacNAc + DC and NK cells to amplify NK-derived IFN γ : role of CD18, ICAM-1, and ICAM-3. *Blood*. 2011;117:1677–86.
94. Pelletier M, Maggi L, Micheletti A, Lazzeri E, Tamassia N, Costantini C, et al. Evidence for a cross-talk between human neutrophils and Th17 cells. *Blood*. 2010;115:335–43.
95. Abi Abdallah DS, Egan CE, Butcher BA, Denkers EY. Mouse neutrophils are professional antigen-presenting cells programmed to instruct Th1 and Th17 T-cell differentiation. *Int Immunol*. 2011;23:317–26.
96. Beauvillain C, Cunin P, Doni A, Scotet M, Jaillon S, Loiry M-L, et al. CCR7 is involved in the migration of neutrophils to lymph nodes. *Blood*. 2011;117:1196–204.
97. Yang C-W, Strong BSI, Miller MJ, Unanue ER. Neutrophils influence the level of antigen presentation during the immune response to protein antigens in adjuvants. *J Immunol*. 2010;185:2927–34.
98. Gregersen PK, Behrens TW. Genetics of autoimmune diseases—disorders of immune homeostasis. *Nat Rev Genet*. 2006;7:917–28.
99. Waldner H. The role of innate immune responses in autoimmune disease development. *Autoimmun Rev*. 2009;8:400–4.
100. Battaglia M. Neutrophils and type 1 autoimmune diabetes. *Curr Opin Hematol*. 2014;21:8–15.
101. Werstuck GH. Molecular and cellular mechanisms by which diabetes mellitus promotes the development of atherosclerosis BT—biochemistry of atherosclerosis. In: Cheema SK, editor. Boston: Springer; 2006. p. 284–304. doi:10.1007/0-387-36279-3_13.
102. You S, Chatenoud L. Autoimmune diabetes: an overview of experimental models and novel therapeutics. *Methods Mol Biol*. 2016;1371:117–42.
103. Szablewski L. Role of immune system in type 1 diabetes mellitus pathogenesis. *Int Immunopharmacol*. 2014;22:182–91.
104. Hevener AL, Olefsky JM, Reichart D, Nguyen MTA, Bandyopadhyay G, Leung H-Y, et al. Macrophage PPAR γ is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. *J Clin Invest*. 2007;117:1658–69.
105. Daneman D. Type 1 diabetes. *Lancet*. 2016;367:847–58. doi:10.1016/S0140-6736(06)68341-4.
106. Patrick C, Rich SS, Nepom GT. Genetics of type 1A diabetes. *N Engl J Med*. 2009;360:1646–54. doi:10.1056/NEJMr0808284.
107. Todd JA. Etiology of type 1 diabetes. *Immunity*. 2010;32:457–67. <http://www.sciencedirect.com/science/article/pii/S1074761310001263>.
108. Erlich H, Valdes AM, Noble J, Carlson JA, Varney M, Concannon P, et al. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. *Diabetes*. 2008;57:1084–92.
109. Rewers M, Ludvigsson J. Environmental risk factors for type 1 diabetes. *Lancet*. 2016;387:2340–8. doi:10.1016/S0140-6736(16)30507-4.
110. Omatsu T, Cepinskas G, Clarson C, Patterson EK, Alharfi IM, Summers K, et al. CXCL1/CXCL8 (GRO α /IL-8) in human diabetic ketoacidosis plasma facilitates leukocyte recruitment to cerebrovascular endothelium in vitro. *Am J Physiol Endocrinol Metab*. 2014;306:E1077–84.

111. Hoffman WH, Burek CL, Waller JL, Fisher LE, Khichi M, Mellick LB. Cytokine response to diabetic ketoacidosis and its treatment. *Clin Immunol*. 2003;108:175–81.
112. Stentz FB, Umpierrez GE, Cuervo R, Kitabchi AE. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. *Diabetes*. 2004;53:2079–86.
113. Stentz FB, Kitabchi AE. Hyperglycemia-induced activation of human T-lymphocytes with de novo emergence of insulin receptors and generation of reactive oxygen species. *Biochem Biophys Res Commun*. 2005;335:491–5.
114. Dahlen E, Dawe K, Ohlsson L, Hedlund G. Dendritic cells and macrophages are the first and major producers of TNF-alpha in pancreatic islets in the nonobese diabetic mouse. *J Immunol*. 1998;160:3585–93.
115. Jun HS, Yoon CS, Zbytniuk L, van Rooijen N, Yoon JW. The role of macrophages in T cell-mediated autoimmune diabetes in nonobese diabetic mice. *J Exp Med*. 1999;189:347–58.
116. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. *Annu Rev Immunol*. 2009;27:451–83.
117. Espinoza-Jiménez A, Peón AN, Terrazas LI. Alternatively activated macrophages in types 1 and 2 diabetes. *Mediators Inflamm*. 2012;2012:815953. doi:10.1155/2012/815953.
118. Cnop M, Welsh N, Jonas JC, Jörns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. *Diabetes*. 2005;54:S97–107.
119. Lee KU, Amano K, Yoon JW. Evidence for initial involvement of macrophage in development of insulinitis in NOD mice. *Diabetes*. 1988;37:989–91.
120. Walker R, Bone AJ, Cooke A, Baird JD. Distinct macrophage subpopulations in pancreas of prediabetic BB/E rats. Possible role for macrophages in pathogenesis of IDDM. *Diabetes*. 1988;37:1301–4.
121. Jun HS, Santamaria P, Lim HW, Zhang ML, Yoon JW. Absolute requirement of macrophages for the development and activation of beta-cell cytotoxic CD8+ T-cells in T-cell receptor transgenic NOD mice. *Diabetes*. 1999;48:34–42.
122. McNelis JC, Olefsky JM. Macrophages, immunity, and metabolic disease. *Immunity*. 2015;41:36–48. doi:10.1016/j.immuni.2014.05.010.
123. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. *Lancet*. 2001;358:221–9.
124. Diana J, Lehuen A. Macrophages and β -cells are responsible for CXCR2-mediated neutrophil infiltration of the pancreas during autoimmune diabetes. *EMBO Mol Med*. 2014;6:1090–104. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4154135/>.
125. Arnush M, Scarim AL, Heitmeier MR, Kelly CB, Corbett JA. Potential role of resident islet macrophage activation in the initiation of autoimmune diabetes. *J Immunol*. 1998;160:2684–91.
126. Andersson A, Kokkola R, Wefer J, Erlandsson-Harris H, Harris RA. Differential macrophage expression of IL-12 and IL-23 upon innate immune activation defines rat autoimmune susceptibility. *J Leukoc Biol*. 2004;76:1118–24.
127. Alleva DG, Pavlovich RP, Grant C, Kaser SB, Beller DI. Aberrant macrophage cytokine production is a conserved feature among autoimmune-prone mouse strains: elevated interleukin (IL)-12 and an imbalance in tumor necrosis factor-alpha and IL-10 define a unique cytokine profile in macrophages from young nonobese. *Diabetes*. 2000;49:1106–15.
128. Maree AFM, Komba M, Finegood DT, Edelstein-Keshet L. A quantitative comparison of rates of phagocytosis and digestion of apoptotic cells by macrophages from normal (BALB/c) and diabetes-prone (NOD) mice. *J Appl Physiol*. 2008;104:157–69.
129. Plesner A, Greenbaum CJ, Gaur LK, Ernst RK, Lernmark A. Macrophages from high-risk HLA-DQB1*0201/*0302 type 1 diabetes mellitus patients are hypersensitive to lipopolysaccharide stimulation. *Scand J Immunol*. 2002;56:522–9.
130. Karavanaki K, Kakleas K, Georga S, Bartzeliotou A, Mavropoulos G, Tsouvalas M, et al. Plasma high sensitivity C-reactive protein and its relationship with cytokine levels in children with newly diagnosed type 1 diabetes and ketoacidosis. *Clin Biochem*. 2012;45:1383–8.
131. Valle A, Giamporcaro GM, Scavini M, Stabellini A, Grogan P, Bianconi E, et al. Reduction of circulating neutrophils precedes and accompanies type 1 diabetes. *Diabetes*. 2013;62:2072–7.
132. Woo M. Regulation of leukocyte-derived matrix metalloproteinases and azurophilic enzymes in human diabetic ketoacidosis. Electronic Thesis and Dissertation Repository; 2015. p. 2869.
133. Woo MMH, Patterson EK, Clarson C, Cepinskas G, Bani-Yaghoob M, Stanimirovic DB, et al. Elevated leukocyte azurophilic enzymes in human diabetic ketoacidosis plasma degrade cerebrovascular endothelial junctional proteins. *Crit Care Med*. 2016;44:e846–53.
134. Wang Y, Xiao Y, Zhong L, Ye D, Zhang J, Tu Y, et al. Increased neutrophil elastase and proteinase 3 and augmented NETosis are closely associated with beta-cell autoimmunity in patients with type 1 diabetes. *Diabetes*. 2014;63:4239–48.
135. Ortmeyer J, Mohsenin V. Inhibition of phospholipase D and superoxide generation by glucose in diabetic neutrophils. *Life Sci*. 1996;59:255–62.
136. Harsunen MH, Puff R, D'Orlando O, Giannopoulou E, Lachmann L, Beyerlein A, et al. Reduced blood leukocyte and neutrophil numbers in the pathogenesis of type 1 diabetes. *Horm Metab Res = Horm. und Stoffwechselforsch = Horm Metab* 2013;45:467–70.
137. Alba-Loureiro TC, Hirabara SM, Mendonca JR, Curi R, Pithon-Curi TC. Diabetes causes marked changes in function and metabolism of rat neutrophils. *J Endocrinol*. 2006;188:295–303.
138. Nabi AHMN, Islam LN, Rahman MM, Biswas KB. Polymorphonuclear neutrophil dysfunctions in streptozotocin-induced type 1 diabetic rats. *J Biochem Mol Biol*. 2005;38:661–7.
139. Diana J, Simoni Y, Furio L, Beaudoin L, Agerberth B, Barrat F, et al. Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. *Nat Med*. 2013;19:65+. http://go.galegroup.com/gate.lib.buffalo.edu/ps/i.do?id=GALE%7CA315921318&v=2.1&u=sunybuff_main&it=i&p=ITOF&sid=7cba2d9bb46d779090317ed39fa78695.
140. Takahashi K, Ohara M, Sasai T, Homma H, Nagasawa K, Takahashi T, et al. Serum CXCL1 concentrations are elevated in type 1 diabetes mellitus, possibly reflecting activity of anti-islet autoimmune activity. *Diabetes Metab Res Rev*. 2011;27:830–3.
141. Citro A, Cantarelli E, Piemonti L. The CXCR1/2 pathway: involvement in diabetes pathophysiology and potential target for T1D interventions. *Curr Diab Rep*. 2015;15:68.
142. Citro A, Valle A, Cantarelli E, Mercalli A, Pellegrini S, Liberati D, et al. CXCR1/2 inhibition blocks and reverses type 1 diabetes in mice. *Diabetes*. 2015;64:1329–40.
143. Hutchings PR, Cooke A. The transfer of autoimmune diabetes in NOD mice can be inhibited or accelerated by distinct cell populations present in normal splenocytes taken from young males. *J Autoimmun*. 1990;3:175–85.
144. Calderon B, Suri A, Unanue ER. In CD4(+) T-cell-induced diabetes, macrophages are the final effector cells that mediate islet β -cell killing: studies from an acute model. *Am J Pathol*. 2006;169:2137–47. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1762478/>.
145. Martin AP, Rankin S, Pitchford S, Charo IF, Furtado GC, Lira SA. Increased expression of CCL2 in insulin-producing cells of transgenic mice promotes mobilization of myeloid cells from the bone marrow, marked insulinitis, and diabetes. *Diabetes*. 2008;57:3025–33. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2570399/>.
146. Firestein GS. Evolving concepts of rheumatoid arthritis. *Nature*. 2003;423:356–61.
147. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. *Annu Rev Immunol*. 1996;14:397–440.
148. Kinne RW, Stuhlmueller B, Burmester G-R. Cells of the synovium in rheumatoid arthritis. *Macrophages*. *Arthritis Res Ther*. 2007;9:224.
149. Klareskog L, Padyukov L, Ronnelid J, Alfredsson L. Genes, environment and immunity in the development of rheumatoid arthritis. *Curr Opin Immunol*. 2006;18:650–5.
150. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. *N Engl J Med*. 2011;365:2205–19.
151. Viatte S, Plant D, Raychaudhuri S. Genetics and epigenetics of rheumatoid arthritis. *Nat Rev Rheumatol*. 2013;9:141–53.
152. Cutolo M. Sex and rheumatoid arthritis: mouse model versus human disease. *Arthritis Rheum*. 2007;56:1–3.
153. Lee T-P, Chiang B-L. Sex differences in spontaneous versus induced animal models of autoimmunity. *Autoimmun Rev*. 2012;11:A422–9.
154. Brandt L, Hedberg H. Impaired phagocytosis by peripheral blood granulocytes in systemic lupus erythematosus. *Scand J Haematol*. 1969;6:348–53.

155. Courtney PA, Crockard AD, Williamson K, Irvine AE, Kennedy RJ, Bell AL. Increased apoptotic peripheral blood neutrophils in systemic lupus erythematosus: relations with disease activity, antibodies to double stranded DNA, and neutropenia. *Ann Rheum Dis*. 1999;58:309–14.
156. Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A, Gizinski A, Yalavarthi S, Knight JS, et al. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. *Sci Transl Med*. 2013;5:178ra40.
157. Wright HL, Moots RJ, Edwards SW. The multifactorial role of neutrophils in rheumatoid arthritis. *Nat Rev Rheumatol*. 2014;10:593–601. doi:10.1038/nrrheum.2014.80.
158. Reynisdottir G, Karimi R, Joshua V, Olsen H, Hensvold AH, Harju A, et al. Structural changes and antibody enrichment in the lungs are early features of anti-citrullinated protein antibody-positive rheumatoid arthritis. *Arthritis Rheumatol*. 2014;66:31–9. doi:10.1002/art.38201.
159. Hamilton JA, Tak PP. The dynamics of macrophage lineage populations in inflammatory and autoimmune diseases. *Arthritis Rheum*. 2009;60:1210–21.
160. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. *Nat Rev Immunol*. 2007;7:429–42.
161. Belcher C, Doherty M, Crouch S. Synovial fluid neutrophil function in RA: the effect of pregnancy associated proteins. *Ann Rheum Dis*. 2002;61:379–80. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1754051/>.
162. Mourao AF, Canhao H, Sousa E, Cascao R, da Costa JB, de Almeida LS, et al. From a neutrophilic synovial tissue infiltrate to a challenging case of rheumatoid arthritis. *Acta Reumatol Port*. 2010;35:228–31.
163. Wipke BT, Allen PM. Essential role of neutrophils in the initiation and progression of a murine model of rheumatoid arthritis. *J Immunol*. 2001;167:1601–8.
164. Brennan FM, Zachariae CO, Chantry D, Larsen CG, Turner M, Maini RN, et al. Detection of interleukin 8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin 8 mRNA by isolated synovial cells. *Eur J Immunol*. 1990;20:2141–4.
165. Eyles JL, Hickey MJ, Norman MU, Croker BA, Roberts AW, Drake SF, et al. A key role for G-CSF-induced neutrophil production and trafficking during inflammatory arthritis. *Blood*. 2008;112:5193–201.
166. Sabroe I, Dower SK, Whyte MKB. The role of Toll-like receptors in the regulation of neutrophil migration, activation, and apoptosis. *Clin Infect Dis*. 2005;41(Suppl 7):S421–6.
167. Milanova V, Ivanovska N, Dimitrova P. TLR2 elicits IL-17-mediated RANKL expression, IL-17, and OPG production in neutrophils from arthritic mice. *Mediators Inflamm*. 2014;2014:643406.
168. Wright HL, Chikura B, Bucknall RC, Moots RJ, Edwards SW. Changes in expression of membrane TNF, NF-(kappa)B activation and neutrophil apoptosis during active and resolved inflammation. *Ann Rheum Dis*. 2011;70:537–43.
169. Rollet-Labelle E, Vaillancourt M, Marois L, Newkirk MM, Poubelle PE, Naccache PH. Cross-linking of IgGs bound on circulating neutrophils leads to an activation of endothelial cells: possible role of rheumatoid factors in rheumatoid arthritis-associated vascular dysfunction. *J Inflamm*. 2013;10:27. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3734015/>.
170. Nurcombe HL, Bucknall RC, Edwards SW. Neutrophils isolated from the synovial fluid of patients with rheumatoid arthritis: priming and activation in vivo. *Ann Rheum Dis*. 1991;50:147–53. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1004363/>.
171. Tolboom TCA, Pieterman E, van der Laan WH, Toes REM, Huidekoper AL, Nelissen RGHH, et al. Invasive properties of fibroblast-like synoviocytes: correlation with growth characteristics and expression of MMP-1, MMP-3, and MMP-10. *Ann Rheum Dis*. 2002;61:975–80.
172. Wang C-H, Dai J-Y, Wang L, Jia J-F, Zheng Z-H, Ding J, et al. Expression of CD147 (EMMPRIN) on neutrophils in rheumatoid arthritis enhances chemotaxis, matrix metalloproteinase production and invasiveness of synoviocytes. *J Cell Mol Med*. 2011;15:850–60.
173. Xue H, Tu Y, Ma T, Liu X, Wen T, Cai M, et al. Lactoferrin inhibits IL-1beta-induced chondrocyte apoptosis through AKT1-induced CREB1 activation. *Cell Physiol Biochem*. 2015;36:2456–65.
174. Tong B, Wan B, Wei Z, Wang T, Zhao P, Dou Y, et al. Role of cathepsin B in regulating migration and invasion of fibroblast-like synoviocytes into inflamed tissue from patients with rheumatoid arthritis. *Clin Exp Immunol*. 2014;177:586–97.
175. Oseas R, Yang HH, Baehner RL, Boxer LA. Lactoferrin: a promoter of polymorphonuclear leukocyte adhesiveness. *Blood*. 1981;57:939–45.
176. Baici A, Salgam P, Cohen G, Fehr K, Boni A. Action of collagenase and elastase from human polymorphonuclear leukocytes on human articular cartilage. *Rheumatol Int*. 1982;2:11–6.
177. Assi LK, Wong SH, Ludwig A, Raza K, Gordon C, Salmon M, et al. Tumor necrosis factor alpha activates release of B lymphocyte stimulator by neutrophils infiltrating the rheumatoid joint. *Arthritis Rheum*. 2007;56:1776–86.
178. Kaplan MJ. Role of neutrophils in systemic autoimmune diseases. *Arthritis Res Ther*. 2013;15:219.
179. Quirke A-M, Lugli EB, Wegner N, Hamilton BC, Charles P, Chowdhury M, et al. Heightened immune response to autocitrullinated *Porphyromonas gingivalis* peptidylarginine deiminase: a potential mechanism for breaching immunologic tolerance in rheumatoid arthritis. *Ann Rheum Dis*. 2014;73:263–9.
180. Deane KD, Norris JM, Holers VM. Preclinical rheumatoid arthritis: identification, evaluation, and future directions for investigation. *Rheum Dis Clin North Am*. 2010;36:213–41.
181. Denny MF, Yalavarthi S, Zhao W, Thacker SG, Anderson M, Sandy AR, et al. A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. *J Immunol*. 2010;184:3284–97.
182. Lubberts E, Joosten LAB, van de Loo FAJ, Schwarzenberger P, Kolls J, van den Berg WB. Overexpression of IL-17 in the knee joint of collagen type II immunized mice promotes collagen arthritis and aggravates joint destruction. *Inflamm Res*. 2002;51:102–4. doi:10.1007/BF02684010.
183. Pratesi F, Dioni I, Tommasi C, Alcaro MC, Paolini I, Barbetti F, et al. Antibodies from patients with rheumatoid arthritis target citrullinated histone 4 contained in neutrophils extracellular traps. *Ann Rheum Dis*. 2014;73:1414–22.
184. Elsaid KA, Jay GD, Chichester CO. Detection of collagen type II and proteoglycans in the synovial fluids of patients diagnosed with non-infectious knee joint synovitis indicates early damage to the articular cartilage matrix. *Osteoarthr Cartil*. 2003;11:673–80.
185. Lefkowitz DL, Mills K, Lefkowitz SS, Bollen A, Moguilevsky N. Neutrophil-macrophage interaction: a paradigm for chronic inflammation. *Med Hypotheses*. 1995;44:58–62.
186. Denkers EY, Butcher BA, Del Rio L, Bennouna S. Neutrophils, dendritic cells and Toxoplasma. *Int J Parasitol*. 2004;34:411–21.
187. Fanger NA, Liu C, Guyre PM, Wardwell K, O'Neil J, Guo TL, et al. Activation of human T cells by major histocompatibility complex class II expressing neutrophils: proliferation in the presence of superantigen, but not tetanus toxoid. *Blood*. 1997;89:4128–35.
188. Radsak M, Iking-Konert C, Stegmaier S, Andrassy K, Hansch GM. Polymorphonuclear neutrophils as accessory cells for T-cell activation: major histocompatibility complex class II restricted antigen-dependent induction of T-cell proliferation. *Immunology*. 2000;101:521–30.
189. Kambayashi T, Laufer TM. Atypical MHC class II-expressing antigen-presenting cells: Can anything replace a dendritic cell? *Nat Rev Immunol*. 2014;14:719–30.
190. Schwaller J, Schneider P, Mhawech-Fauceglia P, McKee T, Myit S, Matthes T, et al. Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness. *Blood*. 2007;109:331–8.
191. Scapini P, Nardelli B, Nadali G, Calzetti F, Pizzolo G, Montecucco C, et al. G-CSF-stimulated neutrophils are a prominent source of functional BlyS. *J Exp Med*. 2003;197:297–302.
192. Scapini P, Bazzoni F, Cassatella MA. Regulation of B-cell-activating factor (BAFF)/B lymphocyte stimulator (BlyS) expression in human neutrophils. *Immunol Lett*. 2008;116:1–6.
193. Puga I, Cols M, Barra CM, He B, Cassis L, Gentile M, et al. B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. *Nat Immunol*. 2012;13:170–80.
194. Mocsai A. Diverse novel functions of neutrophils in immunity, inflammation, and beyond. *J Exp Med*. 2013;210:1283–99.
195. Chakravarti A, Raquil M-A, Tessier P, Poubelle PE. Surface RANKL of toll-like receptor 4-stimulated human neutrophils activates osteoclastic bone resorption. *Blood*. 2009;114:1633–44.

196. Gupta AK, Hasler P, Holzgreve W, Gebhardt S, Hahn S. Induction of neutrophil extracellular DNA lattices by placental microparticles and IL-8 and their presence in preeclampsia. *Hum Immunol*. 2005;66:1146–54.
197. Kennedy A, Fearon U, Veale DJ, Godson C. Macrophages in synovial inflammation. *Front Immunol*. 2011;2:52. from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342259/>.
198. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. *Front Biosci*. 2008;13:453–61.
199. Ma Y, Pope RM. The role of macrophages in rheumatoid arthritis. *Curr Pharm Des*. 2005;11:569–80.
200. Bruhl H, Cihak J, Plachy J, Kunz-Schughart L, Niedermeier M, Denzel A, et al. Targeting of Gr-1+, CCR2+ monocytes in collagen-induced arthritis. *Arthritis Rheum*. 2007;56:2975–85.
201. Ambarus CA, Noordenbos T, de Hair MJH, Tak PP, Baeten DLP. Intimal lining layer macrophages but not synovial sublining macrophages display an IL-10 polarized-like phenotype in chronic synovitis. *Arthritis Res Ther*. 2012;14:R74.
202. Davignon J-L, Hayder M, Baron M, Boyer J-F, Constantin A, Apparailly F, et al. Targeting monocytes/macrophages in the treatment of rheumatoid arthritis. *Rheumatology*. 2013;52:590–8.
203. Takayanagi H. Osteoimmunology: shared mechanisms and cross-talk between the immune and bone systems. *Nat Rev Immunol*. 2007;7:292–304.
204. Burmester GR, Stuhlmuller B, Keyszer G, Kinne RW. Mononuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis? *Arthritis Rheum*. 1997;40:5–18.
205. Vallejo AN, Mugge LO, Klimiuk PA, Weyand CM, Gronzy JJ. Central role of thrombospondin-1 in the activation and clonal expansion of inflammatory T cells. *J Immunol*. 2000;164:2947–54.
206. Kim JY, Kim OY, Paik JK, Kwon DY, Kim H-J, Lee JH. Association of age-related changes in circulating intermediary lipid metabolites, inflammatory and oxidative stress markers, and arterial stiffness in middle-aged men. *Age*. 2013;35:1507–19.
207. Fernandes JC, Martel-Pelletier J, Pelletier J-P. The role of cytokines in osteoarthritis pathophysiology. *Biorheology*. 2002;39:237–46.
208. Blom AB, van der Kraan PM, van den Berg WB. Cytokine targeting in osteoarthritis. *Curr Drug Targets*. 2007;8:283–92.
209. Goldring MB, Otero M, Tsuchimochi K, Ijiri K, Li Y. Defining the roles of inflammatory and anabolic cytokines in cartilage metabolism. *Ann Rheum Dis*. 2008;67(Suppl 3):iii75–82.
210. Milman N, Karsh J, Booth RA. Correlation of a multi-cytokine panel with clinical disease activity in patients with rheumatoid arthritis. *Clin Biochem*. 2010;43:1309–14.
211. Erwig LP, Kluth DC, Walsh GM, Rees AJ. Initial cytokine exposure determines function of macrophages and renders them unresponsive to other cytokines. *J Immunol*. 1998;161:1983–8.
212. Abeles AM, Pillinger MH. The role of the synovial fibroblast in rheumatoid arthritis: cartilage destruction and the regulation of matrix metalloproteinases. *Bull NYU Hosp Jt Dis*. 2006;64:20–4.
213. Roberts CA, Dickinson AK, Taams LS. The interplay between monocytes/macrophages and CD4(+) T cell subsets in rheumatoid arthritis. *Front Immunol*. 2015;6:571. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4652039/>.
214. Vandooren B, Noordenbos T, Ambarus C, Krausz S, Cantaert T, Yermenko N, et al. Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis, including psoriatic arthritis. *Arthritis Rheum*. 2009;60:966–75.
215. Walmsley M, Katsikis PD, Abney E, Parry S, Williams RO, Maini RN, et al. Interleukin-10 inhibition of the progression of established collagen-induced arthritis. *Arthritis Rheum*. 1996;39:495–503.
216. Whalen JD, Lechman EL, Carlos CA, Weiss K, Kovesdi I, Glorioso JC, et al. Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws. *J Immunol*. 1999;162:3625–32.
217. Wallet MA, Wallet SM, Guilfo G, Sleasman JW, Goodenow MM. IFN γ primes macrophages for inflammatory activation by high molecular weight hyaluronan. *Cell Immunol*. 2010;262:84–8.
218. Keffer J, Probert L, Cazarlis H, Georgopoulos S, Kaslaris E, Kioussis D, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. *EMBO J*. 1991;10:4025–31. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC453150/>.
219. Goedkoop AY, Kraan MC, Teunissen MBM, Picavet DJ, de Rie MA, Bos JD, et al. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. *Ann Rheum Dis*. 2004;63:769–73.
220. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. *Pharmacol Ther*. 2008;117:244–79.
221. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. *Lancet*. 1989;2:244–7.
222. Gaffen SL. Role of IL-17 in the pathogenesis of rheumatoid arthritis. *Curr Rheumatol Rep*. 2009;11:365–70. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2811488/>.
223. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. *Arthritis Rheum*. 1993;36:1681–90.
224. Ye L, Wen Z, Li Y, Chen B, Yu T, Liu L, et al. Interleukin-10 attenuation of collagen-induced arthritis is associated with suppression of interleukin-17 and retinoid-related orphan receptor gamma production in macrophages and repression of classically activated macrophages. *Arthritis Res Ther*. 2014;16:R96.
225. Nathan C. Neutrophils and immunity: challenges and opportunities. *Nat Rev Immunol*. 2006;6:173–82.
226. Mauri C, Gray D, Mushtaq N, Londei M. Prevention of arthritis by interleukin 10-producing B cells. *J Exp Med*. 2003;197:489–501.
227. Sasmono RT, Ehrnsperger A, Cronau SL, Ravasi T, Kandane R, Hickey MJ, et al. Mouse neutrophilic granulocytes express mRNA encoding the macrophage colony-stimulating factor receptor (CSF-1R) as well as many other macrophage-specific transcripts and can transdifferentiate into macrophages in vitro in response to CSF-1. *J Leukoc Biol*. 2007;82:111–23.
228. Li J, Hsu H-C, Mountz JD. Managing macrophages in rheumatoid arthritis by reform or removal. *Curr Rheumatol Rep*. 2012;14:445–54.
229. Doherty DE, Downey GP, Worthen GS, Haslett C, Henson PM. Monocyte retention and migration in pulmonary inflammation. Requirement for neutrophils. *Lab Invest*. 1988;59:200–13.
230. Liddiard K, Rosas M, Davies LC, Jones SA, Taylor PR. Macrophage heterogeneity and acute inflammation. *Eur J Immunol*. 2011;41:2503–8. <http://doi.wiley.com/10.1002/eji.201141743>.
231. Herold S, Mayer K, Lohmeyer J. Acute lung injury: how macrophages orchestrate resolution of inflammation and tissue repair. *Front Immunol*. 2011;2:65. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342347/>.
232. Stanford SJ, Pepper JR, Mitchell JA. Release of GM-CSF and G-CSF by human arterial and venous smooth muscle cells: differential regulation by COX-2. *Br J Pharmacol*. 2000;129:835–8.
233. Sindrilaru A, Peters T, Wieschalka S, Baican C, Baican A, Peter H, et al. An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. *J Clin Invest*. 2011;121:985–97. <http://www.jci.org/articles/view/44490>.
234. Wright HL, Moots RJ, Bucknall RC, Edwards SW. Neutrophil function in inflammation and inflammatory diseases. *Rheumatology*. 2010;49:1618–31.
235. Neirinckx V, Coste C, Franzen R, Gothot A, Rogister B, Wislet S. Neutrophil contribution to spinal cord injury and repair. *J Neuroinflammation*. 2014;11:150. <http://www.jneuroinflammation.com/content/11/1/150>.
236. Kasama T, Strieter RM, Standiford TJ, Burdick MD, Kunkel SL. Expression and regulation of human neutrophil-derived macrophage inflammatory protein 1 alpha. *J Exp Med*. 1993;178:63–72.
237. Kumar V, Sharma A. Neutrophils: Cinderella of innate immune system. *Int Immunopharmacol*. 2010;10:1325–34.
238. Kasraie S, Werfel T. Role of macrophages in the pathogenesis of atopic dermatitis. *Mediators Inflamm*. 2013;2013:942375. <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3603294&tool=pmcentrez&rendertype=abstract>.
239. Allison AC, Ferluga J, Prydz H, Schorlemmer HU. The role of macrophage activation in chronic inflammation. *Agents Actions*. 1978;8:27–35.
240. Bohlson SS, O'Conner SD, Hulsebus HJ, Ho M-M, Fraser DA. Complement, C1q, and C1q-related molecules regulate macrophage polarization. *Front Immunol*. 2014;5:402. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4139736/>.

241. Granata F, Frattini A, Loffredo S, Staiano RI, Petraroli A, Ribatti D, et al. Production of vascular endothelial growth factors from human lung macrophages induced by group IIA and group X secreted phospholipases A2. *J Immunol*. 2010;184:5232–41.
242. Jeganathan S, Fiorino C, Naik U, Sun Song H, Harrison RE. Modulation of osteoclastogenesis with macrophage M1- and M2-inducing stimuli. *PLoS ONE*. 2014;9:e104498. doi:10.1371/journal.pone.0104498.
243. Panea C, Farkas AM, Goto Y, Abdollahi-Roodsaz S, Lee C, Koscsó B, et al. Intestinal monocyte-derived macrophages control commensal-specific Th17 responses. *Cell Rep*. 2015;12:1314–24. doi:10.1016/j.celrep.2015.07.040.
244. Griffin GK, Newton G, Tarrío ML, Bu D, Maganto-García E, Azcutia V, et al. IL-17 and TNF- α sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation. *J Immunol*. 2012;188:6287–99.
245. Phillipson M, Kubes P. The neutrophil in vascular inflammation. *Nat Med*. 2011;17:1381–90. doi:10.1038/nm.2514.

Submit your next manuscript to BioMed Central
and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

